A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

NCT00040677 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Sickle Cell Anemia

Interventions

DRUG: Low Dose ICA-17043
DRUG: High dose ICA-17043
DRUG: Placebo

Sponsor

Icagen